论文部分内容阅读
目的 :通过检测肺癌患者在不同临床阶段血清中sIL 6R的水平 ,探索sIL 6R在肺癌患者体内变化的规律 ,为估计病情、判断预后寻找一个客观指标。方法 :Ⅰ期和Ⅳ期肺癌患者各 2 0例 ,对照组 2 0例 ,分别抽取空腹血离心后 ,留取血清 ,用ELISA方法检测。结果 :对照组血清sIL 6R水平为 (46 .83± 6 .70 ) μg/L ;Ⅰ期肺癌组血清sIL 6R水平为 (5 8.6 3± 3.94) μg/L ;Ⅳ期肺癌组血清sIL 6R水平为 (6 9.2 3± 18.73) μg/L ,Ⅰ期和Ⅳ期肺癌组血清sIL 6R水平均明显高于对照组 (P <0 .0 0 1) ;Ⅳ期肺癌组血清sIL 6R水平又明显高于Ⅰ期肺癌组 (P <0 .0 0 1) ;3组之间经方差分析和q检验 ,差异有显著性 (P <0 0 0 1)。结论 :肺癌患者体内存在着sIL 6R的异常表达。Ⅳ期肺癌患者血清中sIL 6R水平高于Ⅰ期患者。当病情进展、病灶范围增大时 ,体内sIL 6R表达增多。提示sIL 6R可能是肺癌患者预后不良的指标。
OBJECTIVE: To detect the level of sIL 6R in serum of patients with lung cancer at different clinical stages and to explore the rule of sIL 6R in patients with lung cancer. To find an objective index to evaluate the prognosis of patients with lung cancer. Methods: Twenty and twenty patients with stage I and IV lung cancer were randomly divided into control group and control group. Serum samples were collected after fasting blood was centrifuged and detected by ELISA. Results: Serum levels of sIL 6R in control group were (46.83 ± 6.70) μg / L, serum sIL 6R level in stage Ⅰ lung cancer group was (5 8.63 ± 3.94) μg / L, serum sIL 6R level in stage Ⅳ lung cancer group (6 9.23 ± 18.73) μg / L, the level of serum sIL 6R in stage Ⅰ and stage Ⅳ lung cancer patients was significantly higher than that in control group (P0.01); stage Ⅳ lung cancer serum sIL 6R levels were significantly higher There was significant difference between the three groups in the stage Ⅰ lung cancer (P <0.01) and the difference between the three groups (P <0.01). Conclusion: Abnormal expression of sIL 6R exists in lung cancer patients. The level of serum sIL 6R in stage Ⅳ lung cancer patients is higher than that in stage Ⅰ patients. When the disease progresses, the range of lesions increases, the body sIL 6R expression increased. Tip sIL 6R may be an indicator of poor prognosis in patients with lung cancer.